Tumoral melanosis mimicking residual melanoma in the setting of talimogene laherparepvec treatment

Tumoral Melanosis and Separate Granulomatous Inflammation due to Talimogene Laherparepvec

(2022) Samantha Shwe et al.   AMERICAN JOURNAL OF DERMATOPATHOLOGY

Tumoral Melanosis in the Setting of Targeted Immunotherapy for Metastatic Melanoma—A Single Institutional Experience and Literature Review

(2020) Andrea Jurgens et al.   AMERICAN JOURNAL OF DERMATOPATHOLOGY

Distinguishing melanophages from tumor in melanoma patients treated with talimogene laherparepvec

(2020) Claire Audrey-Bayan et al.   MELANOMA RESEARCH

Extensive Pigment Incontinence Mimicking Persistent Melanoma After Talimogene Laherparepvec Therapy

(2019) Melissa Danesh et al.   JAMA Dermatology

Talimogene laherparepvec: review of its mechanism of action and clinical efficacy and safety

(2019) Steven S Raman et al.   Immunotherapy

The pleiotropy associated with de novo variants in CHD4, CNOT3, and SETD5 extends to moyamoya angiopathy

(2019) Amélie Pinard et al.   GENETICS IN MEDICINE

Granulomatous Tumoral Melanosis Associated With Pembrolizumab Therapy

(2018) Randi Woodbeck et al.   AMERICAN JOURNAL OF DERMATOPATHOLOGY

Extensive tumoral melanosis associated with ipilimumab-treated melanoma

(2016) K. Staser et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial

(2016) Kevin Harrington et al.   OncoTargets and Therapy

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

(2015) Robert H.I. Andtbacka et al.   JOURNAL OF CLINICAL ONCOLOGY